June 16 Quick Takes: Takeda out-licenses neurology pipeline to Neurocrine; plus Illumina challenge blocks BGI, FDA approves a pair of firsts and more

Takeda receives $120M up front for seven neurology therapies
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) granted Neurocrine Biosciences Inc. (NASDAQ:NBIX) an exclusive, worldwide license to seven neurology programs: three mood disorder therapies that have completed Phase I testing, and four preclinical candidates. Takeda will receive $120 million up front and be eligible for up

Read the full 531 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE